Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials
- PMID: 34224688
- DOI: 10.1016/j.ajog.2021.06.090
Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials
Abstract
Objective: Combined oral contraceptives are often considered a treatment option for women with premenstrual syndrome or premenstrual dysphoric disorder also seeking contraception, but evidence for this treatment is scarce. We aimed to determine (1) the level of evidence for the efficacy of combined oral contraceptives in managing premenstrual depressive symptoms and overall premenstrual symptomatology and (2) the comparative efficacy of combined oral contraceptives (the International Prospective Register of Systematic Reviews registration number CRD42020205510).
Data sources: We searched Cochrane Central Register of Controlled Trials, PubMed, Web of Science, PsycINFO, EMCare, and Embase from inception to June 3, 2021.
Study eligibility criteria: All randomized clinical trials that evaluated the efficacy of combined oral contraceptives in women with premenstrual syndrome or premenstrual dysphoric disorder were considered eligible for inclusion in this meta-analysis.
Study appraisal and synthesis methods: A random effect Bayesian pairwise and network meta-analysis was conducted with change in premenstrual depressive symptoms and overall premenstrual symptomatology between baseline and 3 cycles as outcome. Certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
Results: Of 3664 records, 9 eligible trials were included that studied 1205 women with premenstrual syndrome or premenstrual dysphoric disorder (mean age per study range, 24.6-36.5 years). The pairwise meta-analysis revealed that combined oral contraceptives were more efficacious than placebo in treating overall premenstrual symptomatology (standardized mean difference, 0.41; 95% credible interval, 0.17-0.67), but not premenstrual depressive symptoms specifically (standardized mean difference, 0.22; 95% credible interval, -0.06 to 0.47). However, none of the combined oral contraceptives were more effective than each other in reducing premenstrual depressive symptoms and overall premenstrual symptomatology.
Conclusion: Combined oral contraceptives may improve overall premenstrual symptomatology in women with premenstrual syndrome or premenstrual dysphoric disorder, but not premenstrual depressive symptoms. There is no evidence for one combined oral contraceptive being more efficacious than any other.
Keywords: combined oral contraceptives; depressive symptoms; efficacy; network meta-analysis; overall symptomatology; premenstrual dysphoric syndrome; premenstrual syndrome; randomized clinical trials; systematic review.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
-
Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006586. doi: 10.1002/14651858.CD006586.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2023 Jun 23;6:CD006586. doi: 10.1002/14651858.CD006586.pub5. PMID: 22336820 Updated. Review.
-
Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006586. doi: 10.1002/14651858.CD006586.pub3. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006586. doi: 10.1002/14651858.CD006586.pub4. PMID: 19370644 Updated. Review.
-
Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006586. doi: 10.1002/14651858.CD006586.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006586. doi: 10.1002/14651858.CD006586.pub3. PMID: 18254106 Updated. Review.
-
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].Zhonghua Fu Chan Ke Za Zhi. 2014 Jul;49(7):506-9. Zhonghua Fu Chan Ke Za Zhi. 2014. PMID: 25327732 Clinical Trial. Chinese.
-
The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis.Am J Obstet Gynecol. 2017 Aug;217(2):150-166. doi: 10.1016/j.ajog.2017.02.028. Epub 2017 Feb 22. Am J Obstet Gynecol. 2017. PMID: 28237870 Review.
Cited by
-
Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).Front Glob Womens Health. 2024 Apr 9;5:1395863. doi: 10.3389/fgwh.2024.1395863. eCollection 2024. Front Glob Womens Health. 2024. PMID: 38655395 Free PMC article.
-
(S)-S-adenosylmethionine in the treatment of pre-menstrual disorders in adult women: A protocol for an open-label pilot study.Contemp Clin Trials Commun. 2024 Mar 30;39:101297. doi: 10.1016/j.conctc.2024.101297. eCollection 2024 Jun. Contemp Clin Trials Commun. 2024. PMID: 38590512 Free PMC article.
-
Depression in Women: Potential Biological and Sociocultural Factors Driving the Sex Effect.Neuropsychobiology. 2024;83(1):2-16. doi: 10.1159/000531588. Epub 2024 Jan 25. Neuropsychobiology. 2024. PMID: 38272005 Free PMC article. Review.
-
Diagnostic validity of premenstrual dysphoric disorder: revisited.Front Glob Womens Health. 2023 Nov 27;4:1181583. doi: 10.3389/fgwh.2023.1181583. eCollection 2023. Front Glob Womens Health. 2023. PMID: 38090047 Free PMC article. Review.
-
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.CNS Drugs. 2023 Aug;37(8):679-693. doi: 10.1007/s40263-023-01030-7. Epub 2023 Aug 5. CNS Drugs. 2023. PMID: 37542704 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical